| Background and description
Blood compatible materials relate to construction materials used in devices
intended to be in contact with circulating blood, either as externally
communicating temporary devices or as permanent implants. In both situations
numerous applications involve critical life support, as e.g. vascular
grafting and coronary stenting. Although the choice of materials used
in today’s devices to a large extent have been made empirically, or even
by accident, the widespread use of such devices demonstrate that they may
be used clinically with good results. There are still significant clinical
problems, which are poorly understood but likely to be related to
biocompatibility aspects. It is anticipated that the solution of these
problems could substantially improve the quality of medical care with
blood-contacting devices.
The vision of the project was to establish a comprehensive knowledge of the
molecular and cellular mechanisms that regulates biocompatibility, in
particular blood compatibility, of biomaterials in contact with blood and
other bodily fluids. This knowledge will be utilised in designing materials
with improved performance characteristics in combination with protocols for
selective inhibition to be used in cardiovascular applications.
Scientific results
Three doctoral dissertations have been presented (see Publications 5:1-3)
including 12 original papers. Twenty-one additional papers and four review
papers have been published separately (see Publications).
Two in vitro test models designed for evaluation of biomaterials using fresh
human blood have been documented and widely used to study heparin modified
surfaces (5:10, 5:13 ), stent grafts modified with immobilised heparin (5:15),
surfaces with immobilised factor H (5:9), titanium and other interesting
metals (5:5, 5:26), the effect of specific inhibition of complement (5:6)
and further interactions with complement (5:7-8, 5:10, 5:15 ), different
aspects of activation of coagulation (5:4-5, 5:10, 5:13, 5:16, 5:18) including
cellular interactions (5:4-5, 5:10, 5:13-15).
A clinical study has shown less activation of coagulation and inflammation
during coronary bypass grafting, using a heparin coated extracorporeal circuit
compared with a regular non-modified circuit (5:11-12). Photon electron
spectroscopy and QCM-D have been utilised to characterise a new heparin
surface (5:17). QCM-D has also been used to describe the formation of a
complement convertase (5:7-8), which has also been studied using surface
plasmon resonance (5:25). Phosphorylation of plasma proteins such as C3,
fibrinogen, vitronectin, and factor XI, by a protein kinase released by
activated platelets has been thoroughly described and shown to effect
biological activity with respect to both complement and coagulation
(5:19-24). The in vitro test models have proven useful to study blood
compatibility of islets of Langerhans, which has resulted in a number
of interesting papers (5:27-29, 5:33-34).
We conclude that all seven long-term goals which were put forward in
the original application have been fulfilled: all aspects have been addressed
and discussed in original peer-review papers and in review articles.
|